$RGEN
REPLIGEN CORP Stock $rgen

$rgen Overview Financials Valuation SEC Filings Company Website

2012 Q4 Form 10-K Financial Statement

#000119312513109050 Filed on March 15, 2013

Income Statement

Concept	2012 Q4	2012 Q3	2011 Q4
Revenue	$18.81M	$15.10M	$7.165M
YoY Change	162.58%	75.0%	0.92%
Cost Of Revenue	$5.920M	$6.419M	$1.511M
YoY Change	291.79%	206.69%	-20.47%
Gross Profit	$12.89M	$8.685M	$5.654M
YoY Change	128.05%	32.84%	8.73%
Gross Profit Margin	68.53%	57.5%	78.91%
Selling, General & Admin	$3.253M	$3.126M	$4.268M
YoY Change	-23.78%	25.39%	113.4%
% of Gross Profit	25.23%	35.99%	75.49%
Research & Development	$2.343M	$2.433M	$2.870M
YoY Change	-18.36%	-20.88%	-1.03%
% of Gross Profit	18.17%	28.01%	50.76%
Depreciation & Amortization	$920.0K	$890.0K	$460.0K
YoY Change	100.0%	122.5%	0.0%
% of Gross Profit	7.14%	10.25%	8.14%
Operating Expenses	$5.596M	$5.559M	$7.138M
YoY Change	-21.6%	-0.16%	45.67%
Operating Profit	$6.411M	$2.188M	-$1.538M
YoY Change	-516.84%	296.38%	-612.67%
Interest Expense	$14.00K	-$7.000K	$28.00K
YoY Change	-50.0%	-107.0%	-72.0%
% of Operating Profit	0.22%	-0.32%
Other Income/Expense, Net	-$41.00K	-$500.0K	-$623.0K
YoY Change	-93.42%
Pretax Income	$6.418M	$1.790M	-$2.146M
YoY Change	-399.07%	195.87%	-636.5%
Income Tax	-$3.135M	-$16.00K	$16.00K
% Of Pretax Income	-48.85%	-0.89%
Net Earnings	$9.553M	$1.806M	-$2.162M
YoY Change	-541.86%	198.51%	-640.5%
Net Earnings / Revenue	50.78%	11.96%	-30.17%
Basic Earnings Per Share	$0.31	$0.06	-$0.07
Diluted Earnings Per Share	$0.30	$0.06	-$0.07
COMMON SHARES
Basic Shares Outstanding	31.13M shares	30.95M shares	30.72M shares
Diluted Shares Outstanding	31.60M shares	31.26M shares	30.72M shares

Balance Sheet

Concept	2012 Q4	2012 Q3	2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$40.10M	$30.30M	$26.60M
YoY Change	50.75%	-39.16%	-47.95%
Cash & Equivalents	$29.21M	$18.39M	$11.17M
Short-Term Investments	$10.80M	$11.90M	$15.40M
Other Short-Term Assets	$36.73K	$1.100M	$82.30K
YoY Change	-55.37%	22.22%	-96.26%
Inventory	$11.14M	$10.77M	$13.36M
Prepaid Expenses
Receivables	$4.159M	$7.636M	$2.825M
Other Receivables	$9.100M	$4.000M	$3.200M
Total Short-Term Assets	$66.21M	$53.79M	$46.89M
YoY Change	41.19%	-10.35%	-20.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.952M	$10.12M	$10.74M
YoY Change	-7.31%	462.02%	366.84%
Goodwill	$994.0K	$994.0K	$994.0K
YoY Change	0.0%
Intangibles	$7.182M	$7.377M	$7.795M
YoY Change	-7.87%
Long-Term Investments	$9.900M	$12.40M	$9.400M
YoY Change	5.32%	45.88%	2.17%
Other Assets	$2.800M	$200.0K	$200.0K
YoY Change	1300.0%	0.0%	0.0%
Total Long-Term Assets	$30.80M	$31.10M	$29.16M
YoY Change	5.62%	146.86%	109.8%
TOTAL ASSETS
Total Short-Term Assets	$66.21M	$53.79M	$46.89M
Total Long-Term Assets	$30.80M	$31.10M	$29.16M
Total Assets	$97.01M	$84.90M	$76.06M
YoY Change	27.55%	16.94%	4.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.454M	$1.767M	$1.422M
YoY Change	72.53%	194.45%	103.21%
Accrued Expenses	$8.298M	$7.269M	$6.041M
YoY Change	37.36%	142.3%	187.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.75M	$9.036M	$7.464M
YoY Change	44.06%	115.14%	107.32%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.133M	$1.900M	$2.469M
YoY Change	-13.61%	216.68%	311.57%
Total Long-Term Liabilities	$2.133M	$1.900M	$2.469M
YoY Change	-13.61%	216.68%	311.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.75M	$9.036M	$7.464M
Total Long-Term Liabilities	$2.133M	$1.900M	$2.469M
Total Liabilities	$12.89M	$10.94M	$9.933M
YoY Change	29.73%	132.68%	136.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$105.2M	-$114.7M	-$119.3M
YoY Change	-11.87%
Common Stock	$312.0K	$310.5K	$307.1K
YoY Change	1.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$84.12M	$73.70M	$65.99M
YoY Change
Total Liabilities & Shareholders Equity	$97.01M	$84.90M	$76.06M
YoY Change	27.55%	16.94%	4.04%

Cashflow Statement

Concept	2012 Q4	2012 Q3	2011 Q4
OPERATING ACTIVITIES
Net Income	$9.553M	$1.806M	-$2.162M
YoY Change	-541.86%	198.51%	-640.5%
Depreciation, Depletion And Amortization	$920.0K	$890.0K	$460.0K
YoY Change	100.0%	122.5%	0.0%
Cash From Operating Activities	$7.230M	$2.470M	$4.870M
YoY Change	48.46%	1546.67%	334.82%
INVESTING ACTIVITIES
Capital Expenditures	-$430.0K	-$320.0K	-$240.0K
YoY Change	79.17%	88.24%	41.18%
Acquisitions
YoY Change
Other Investing Activities	$3.570M	-$980.0K	-$3.970M
YoY Change	-189.92%	-128.91%	-36.58%
Cash From Investing Activities	$3.140M	-$1.290M	-$4.200M
YoY Change	-174.76%	-140.06%	-34.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	270.0K	760.0K	0.000
YoY Change		-330.3%	-100.0%
NET CHANGE
Cash From Operating Activities	7.230M	2.470M	4.870M
Cash From Investing Activities	3.140M	-1.290M	-4.200M
Cash From Financing Activities	270.0K	760.0K	0.000
Net Change In Cash	10.64M	1.940M	670.0K
YoY Change	1488.06%	-36.18%	-112.48%
FREE CASH FLOW
Cash From Operating Activities	$7.230M	$2.470M	$4.870M
Capital Expenditures	-$430.0K	-$320.0K	-$240.0K
Free Cash Flow	$7.660M	$2.790M	$5.110M
YoY Change	49.9%	771.88%	296.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31219541	shares
CY2011Q3	rgen	Letters Of Credit LettersOfCredit	200000
CY2011Q3	rgen	Lease Agreement Term LeaseAgreementTerm	P11Y
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.08
CY2010Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	50000
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9794509
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2566450	shares
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	878459
CY2011Q4	us-gaap	Goodwill Goodwill	994000
CY2011Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	499776
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18614715
CY2011Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	32000
CY2011Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	31839
CY2011Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	35000
CY2011Q4	us-gaap	Other Assets Current OtherAssetsCurrent	82304
CY2011Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	5936578
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28476000
CY2011Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-105000
CY2011Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	15000
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	65987000
CY2011Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	24850448
CY2011Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	9435350
CY2011Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	12011154
CY2011Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3563395
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2011Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	275258
CY2011Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	715155
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2741738
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30714757	shares
CY2011Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	48000
CY2011Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	871086
CY2011Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	15421436
CY2011Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	89000
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1422483
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20065000
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	469046
CY2011Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4277000
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2469412
CY2011Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2197226
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Prepaid Insurance PrepaidInsurance	251418
CY2011Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	566542
CY2011Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4166000
CY2011Q4	rgen	Prepaid Expenses And Other Current Assets PrepaidExpensesAndOtherCurrentAssets	878459
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-119306614
CY2011Q4	us-gaap	Assets Assets	76056814
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.05
CY2011Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	149000
CY2011Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	136881
CY2011Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3206840
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2825414
CY2011Q4	us-gaap	Inventory Net InventoryNet	13363073
CY2011Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	11032
CY2011Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	29162008
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	76056814
CY2011Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	5083852
CY2011Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	200000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11167745
CY2011Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	4694
CY2011Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	8161711
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30714757	shares
CY2011Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7795239
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	113627
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6041038
CY2011Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1244451
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7463521
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	10000
CY2011Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3863100
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2823400	shares
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	307148
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2011Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	366472
CY2011Q4	us-gaap	Assets Current AssetsCurrent	46894806
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2011Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	28508000
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2011Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	6041038
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7877296
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10737419
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	184872839
CY2011Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	24856786
CY2011Q4	us-gaap	Interest Receivable InterestReceivable	106695
CY2011Q4	rgen	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	142695
CY2011Q4	rgen	Marketable Securities Remaining Maturity MarketableSecuritiesRemainingMaturity	P9M27D
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2222000
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	20745938
CY2012Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	9914855
CY2012Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value Current BusinessAcquisitionContingentConsiderationAtFairValueCurrent	1322000
CY2012Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	12802978
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4064317
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2011Q4	rgen	Capitalized Research And Development Expenses CapitalizedResearchAndDevelopmentExpenses	13714
CY2011Q4	rgen	Prepaid Services And Professional Fees PrepaidServicesAndProfessionalFees	424328
CY2012Q2	dei	Entity Public Float EntityPublicFloat	126339916
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1304887
CY2012Q4	us-gaap	Goodwill Goodwill	994000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2222000
CY2012Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1459680
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	20279301
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3046000
CY2012Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	416580
CY2012Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1376877
CY2012Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	10845195
CY2012Q4	us-gaap	Share Price SharePrice	6.28
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	36730
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4112478
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18307000
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	2974000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1000000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1447600	shares
CY2012Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	329000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	84124596
CY2012Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1605995
CY2012Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	338814
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	692212
CY2012Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2783183
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1000000
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3634839
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.39
CY2012Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses2	1000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4854412
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31195041	shares
CY2012Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	72000
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	418800
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2222000
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4158758
CY2012Q4	us-gaap	Inventory Net InventoryNet	11143695
CY2012Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	15479
CY2012Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	30800712
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	97010163
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	441000
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	2667000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2222000
CY2012Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions	7	Investment
CY2012Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	10845195
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2454238
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15041000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1000000
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	599120
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4152000
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2133339
CY2012Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2899076
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1655000
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	10835995
CY2012Q4	us-gaap	Prepaid Insurance PrepaidInsurance	365167
CY2012Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	98162
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2160000
CY2012Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	2557384
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-105150577
CY2012Q4	us-gaap	Assets Assets	97010163
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.20
CY2012Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	477000
CY2012Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	154000
CY2012Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	9130515
CY2012Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	5200271
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	200000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	4570615
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29209821
CY2012Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	1367
CY2012Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	8565112
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31195041	shares
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7182012
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	5611000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2186609	shares
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1911970
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	43000
	us-gaap	Operating Income Loss OperatingIncomeLoss	1712431
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	11810869
CY2012Q4	rgen	Prepaid Expenses And Other Current Assets PrepaidExpensesAndOtherCurrentAssets	1304887
CY2012Q4	rgen	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	18300
CY2012Q4	rgen	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	9914855
CY2012Q4	rgen	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber	739009	shares
	us-gaap	Costs And Expenses CostsAndExpenses	19672208
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-25447
CY2012Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3893210	shares
CY2012Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value Noncurrent BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent	1033000
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8297990
CY2012Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1937238
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1000000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1000000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10752228
CY2012Q4	us-gaap	Contractual Obligation ContractualObligation	2872000
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	10000
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2966900
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2315090	shares
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	311950
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1383100
CY2012Q4	us-gaap	Assets Current AssetsCurrent	66209451
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21353000
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	16154000
CY2012Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8297990
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10326840
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9952461
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	187051253
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.21
CY2012Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	20760050
CY2012Q4	us-gaap	Interest Receivable InterestReceivable	140363
CY2012Q4	rgen	Available For Sale Securities Debt Maturities One Through Two Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesOneThroughTwoYearsAmortizedCost	9909943
CY2012Q4	rgen	Capitalized Research And Development Expenses CapitalizedResearchAndDevelopmentExpenses	15354
CY2012Q4	rgen	Prepaid Services And Professional Fees PrepaidServicesAndProfessionalFees	747273
CY2001Q1	rgen	Lease Agreement Term LeaseAgreementTerm	P10Y
CY2007Q1	rgen	Lease Agreement Term LeaseAgreementTerm	P5Y
CY2008Q1	rgen	Lease Agreement Term LeaseAgreementTerm	P2Y
CY2010Q1	us-gaap	Stockholders Equity StockholdersEquity	66120376
CY2010Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12526040
CY2011Q1	us-gaap	Stockholders Equity StockholdersEquity	67086704
CY2011Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	50000
CY2011Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14203544
	us-gaap	Interest Expense InterestExpense	12683
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.95
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	58095140
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	748000
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	56850
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-291824
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1987178
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	54225000
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	1102000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0181	pure
	us-gaap	Share Based Compensation ShareBasedCompensation	748235
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.06
	us-gaap	Investment Income Net InvestmentIncomeNet	287430
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1274247
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	25758
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1787683
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4488122
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	317982
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2731531
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5758	pure
	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	1160775
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	708311
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30949264	shares
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	601141
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1987178
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.06
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8744548
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-31092
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6360	pure
	us-gaap	Royalty Revenue RoyaltyRevenue	9573770
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30778430	shares
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-263570
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	510000
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	170834	shares
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4186670
	us-gaap	Revenues Revenues	21384639
	us-gaap	Depreciation Depreciation	1141000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0262	pure
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1771100	shares
	us-gaap	Net Income Loss NetIncomeLoss	1987178
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5580215
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	450600
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue	817000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	134000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-408224
	us-gaap	Costs And Expenses CostsAndExpenses	24557314
	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	52905
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	11487
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	8000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1107067
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	13215053
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	247222
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-623094
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-2826
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	730136
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1498998
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	45624819
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	1466000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-542939
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0125	pure
	us-gaap	Share Based Compensation ShareBasedCompensation	730136
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Investment Income Net InvestmentIncomeNet	161053
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	330867
	us-gaap	Other Noncash Expense OtherNoncashExpense	28182
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1274597
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.010	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
	us-gaap	Gain On Purchase Of Business GainOnPurchaseOfBusiness	427478
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	25
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2310745
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5010610
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.033	pure
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	575455
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3035799
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5309	pure
	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	1315315
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	190007
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30774467	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	25
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3551969
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	330867
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	107289
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1596881
	us-gaap	Income Tax Expense Benefit Continuing Operations IncomeTaxExpenseBenefitContinuingOperations	15744
	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	68926
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9461960
	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.043	pure
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-330842
	rgen	Income Tax Reconciliation Gain On Bargain Purchase IncomeTaxReconciliationGainOnBargainPurchase	112427
	rgen	Deferred Tax Assets Valuation Allowance Increase Decrease DeferredTaxAssetsValuationAllowanceIncreaseDecrease	73000
	rgen	Effective Income Tax Rate Reconciliation Transaction Costs EffectiveIncomeTaxRateReconciliationTransactionCosts	0.151	pure
	rgen	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.137	pure
	rgen	Effective Income Tax Rate Reconciliation Bargain Purchase Gain EffectiveIncomeTaxRateReconciliationBargainPurchaseGain	-0.070	pure
	rgen	Income Tax Reconciliation Transaction Costs IncomeTaxReconciliationTransactionCosts	240842
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.5576	pure
	us-gaap	Royalty Revenue RoyaltyRevenue	10235194
	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.012	pure
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	246587
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30774467	shares
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	870252
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	528000
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.340	pure
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5157135
	us-gaap	Revenues Revenues	23450247
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.154	pure
	us-gaap	Depreciation Depreciation	1117000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	49465924
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	730000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	15744
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0238	pure
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2823400	shares
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	26290378
	us-gaap	Net Income Loss NetIncomeLoss	-1612625
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9050382
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	694238
	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-19287
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15744
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-5092
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue	804000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6338
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	158000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	243182
	us-gaap	Interest Expense InterestExpense	27773
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.89
	rgen	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	218989
CY2007Q2	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	0.01
CY2007Q2	rgen	Stock Issued During Period Shares Common Stock Warrants StockIssuedDuringPeriodSharesCommonStockWarrants	150000	shares
CY2007Q2	rgen	Warrant Term WarrantTerm	P7Y
CY2011	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-05-31
CY2011	rgen	Lease Agreement Area LeaseAgreementArea	56000	sqft
CY2011	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	48000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0089	pure
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	248143
CY2011	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.4976	pure
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1596881
CY2011	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	-32226
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.5354	pure
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1845024
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0106	pure
CY2011	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P8Y
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15774
CY2011	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	179000
CY2011	rgen	Provision For Deferred Income Tax Expense Benefit ProvisionForDeferredIncomeTaxExpenseBenefit	15774
CY2001	rgen	Lease Agreement Area LeaseAgreementArea	25000	sqft
CY2007	rgen	Lease Agreement Area LeaseAgreementArea	2500	sqft
CY2011	us-gaap	Costs And Expenses CostsAndExpenses	27665095
CY2011	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	96141
CY2011	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-58285
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-374071
CY2011	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	14961397
CY2011	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-60404
CY2011	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-5597
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1003266
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43509
CY2011	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	83650417
CY2011	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	1346000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2011	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-14793
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0181	pure
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	1003266
CY2011	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2011	us-gaap	Investment Income Net InvestmentIncomeNet	356729
CY2011	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1674528
CY2011	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2011	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
CY2011	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6571
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3231763
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1503980
CY2011	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	2.210	pure
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	524666
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1677504
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5594	pure
CY2011	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	1537666
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-986340
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue	993000
CY2011	rgen	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	5.757	pure
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30781881	shares
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6571
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	689569
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-43509
CY2011	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	66126
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12528819
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-1.520	pure
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-50279
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6360	pure
CY2011	us-gaap	Royalty Revenue RoyaltyRevenue	12329627
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.000	pure
CY2011	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-265706
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-43509
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30781881	shares
CY2011	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-247164
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	686000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.340	pure
CY2011	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5579759
CY2011	us-gaap	Revenues Revenues	27291024
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-6.107	pure
CY2011	us-gaap	Depreciation Depreciation	1496000
CY2011	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	84329731
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1003000
CY2011	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	56850
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0283	pure
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2580600	shares
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-43509
CY2011	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8018851
CY2011	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	216602
CY2011	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	383237
CY2011	us-gaap	Interest Expense InterestExpense	26167
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.11
CY2011	rgen	Deferred Tax Assets Valuation Allowance Increase Decrease DeferredTaxAssetsValuationAllowanceIncreaseDecrease	2227000
CY2011	rgen	Effective Income Tax Rate Reconciliation Transaction Costs EffectiveIncomeTaxRateReconciliationTransactionCosts	0.000	pure
CY2011	rgen	Effective Income Tax Rate Reconciliation Bargain Purchase Gain EffectiveIncomeTaxRateReconciliationBargainPurchaseGain	0.000	pure
CY2011	rgen	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	250483
CY2012	dei	Trading Symbol TradingSymbol	RGEN
CY2012	dei	Entity Registrant Name EntityRegistrantName	REPLIGEN CORP
CY2012	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012	dei	Amendment Flag AmendmentFlag	false
CY2012	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2012	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2012	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2012	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012	dei	Document Type DocumentType	10-K
CY2012	dei	Document Period End Date DocumentPeriodEndDate	2012-12-31
CY2012	dei	Entity Central Index Key EntityCentralIndexKey	0000730272
CY2012	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2012	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012	us-gaap	Costs And Expenses CostsAndExpenses	51183423
CY2012	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-2915673
CY2012	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	357866
CY2012	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1110791
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1384000
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	11083113
CY2012	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	41834188
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1001546
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y11M16D
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	26403
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.45
CY2012	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	3021000
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y18D
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	1024152
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.65
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.44
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1024152
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	15954380
CY2012	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	43214487
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	312630
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	3944996
CY2012	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	609400	shares
CY2012	us-gaap	Investment Income Net InvestmentIncomeNet	218604
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	95768
CY2012	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Concentrations of Credit Risk and Significant Customers</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments that subject the Company to significant concentrations of credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. Per the Company’s investment policy, cash equivalents and marketable securities are invested in financial instruments with high credit ratings and credit exposure to any one issue, issuer (with the exception of U.S. treasury obligations) and type of instrument is limited. At December 31, 2012 and 2011, the Company had no investments associated with foreign exchange contracts, options contracts or other foreign hedging arrangements.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Concentration of credit risk with respect to accounts receivable is limited to customers to whom the Company makes significant sales. While a reserve for the potential write-off of accounts receivable is maintained, the Company has not written off any significant accounts to date. To control credit risk, the Company performs regular credit evaluations of its customers’ financial condition.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Revenue from significant customers as a percentage of the Company’s total revenue is as follows:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="52%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year ended</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>December  31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Nine Months ended December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year ended</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>March  31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2010</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Orencia<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="POSITION: relative; BOTTOM: 0.8ex; VERTICAL-ALIGN: baseline">®</sup></font> Royalties from Bristol</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">24</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">37</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">37</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">38</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Bioprocessing Customer A</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">42</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">44</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">45</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">42</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> </tr> </table> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">  </p> <p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Significant accounts receivable balances as a percentage of the Company’s total trade accounts receivable and royalties and other receivable balances are as follows:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr> <td width="70%"></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="14%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December 31, 2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December 31, 2011</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Orencia<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="POSITION: relative; BOTTOM: 0.8ex; VERTICAL-ALIGN: baseline">®</sup></font> Royalties from Bristol</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">31</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">53</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Bioprocessing Customer A</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">31</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Pfizer</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">38</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—  </font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> </tr> </table> </div>
CY2012	us-gaap	Other Noncash Expense OtherNoncashExpense	604133
CY2012	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3508592
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.256	pure
CY2012	us-gaap	Gain On Purchase Of Business GainOnPurchaseOfBusiness	314244
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1159064
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	13439608
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2840881
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	140000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.06
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.032	pure
CY2012	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1263647
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	18042076
CY2012	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	2213004
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-30266
CY2012	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M4D
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31253434	shares
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1159064
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1211343
CY2012	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1790551
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	11271406
CY2012	us-gaap	Income Tax Expense Benefit Continuing Operations IncomeTaxExpenseBenefitContinuingOperations	-2884631
CY2012	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	67276
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.46
CY2012	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Organization and Nature of Business</b></font></td> </tr> </table> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Repligen Corporation (“Repligen” or the “Company”) is a life sciences company that develops, manufactures and markets high-value, consumable bioprocessing products for life sciences companies and biopharmaceutical manufacturing companies worldwide. The Company is a world-leading manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. Repligen also supplies several growth factor products used to increase cell culture productivity during the biomanufacturing process. In the burgeoning area of disposable biomanufacturing technologies, the Company has developed and currently markets a series of OPUS (Open-Platform, User-Specified) chromatography columns for use in clinical-scale manufacturing. The Company generally manufactures and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sells its chromatography columns, as well as media and quality test kits, directly to biopharmaceutical companies or contract manufacturing organizations. Repligen refers to these activities as its bioprocessing business. The Company manufactures its products in production facilities in the United States and Sweden.</font></p> <p style="PADDING-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Historically, Repligen also conducted activities aimed at developing proprietary therapeutic drug candidates, often with a potential of entering into a collaboration with a larger commercial stage pharmaceutical or biotechnology company in respect of these programs. In addition, the Company has out-licensed certain intellectual property to Bristol-Myers Squibb Company, or Bristol, from which Repligen receives royalties on Bristol’s net sales in the United States of their product Orencia<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="POSITION: relative; BOTTOM: 0.8ex; VERTICAL-ALIGN: baseline">®</sup></font>. As part of Repligen’s strategic decision in 2012 to focus the Company’s efforts on its core bioprocessing business, the Company scaled back efforts on its clinical development programs and increased its efforts to find collaboration partners to finish their development and, if successful, commercialize these therapeutic drug candidates.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company is subject to a number of risks typically associated with companies in the biotechnology industry. These risks principally include the Company’s dependence on key customers, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with the FDA and other governmental regulations and approval requirements, as well as the ability to grow the Company’s business and obtain adequate funding to finance this growth.</font></p> </div>
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10489811
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.006	pure
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1159064
CY2012	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	-84265
CY2012	us-gaap	Royalty Revenue RoyaltyRevenue	20432348
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001	pure
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-7272092
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	11175638
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30914424	shares
CY2012	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	618000
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2734239
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2183000
CY2012	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	339010	shares
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	267600	shares
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M28D
CY2012	us-gaap	Cost Of Goods Sold CostOfGoodsSold	24957243
CY2012	us-gaap	Revenues Revenues	62266536
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.645	pure
CY2012	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	736850
CY2012	us-gaap	Depreciation Depreciation	2492000
CY2012	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	39109959
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1024000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0
CY2012	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	115307
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3143268
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1296700	shares
CY2012	us-gaap	Net Income Loss NetIncomeLoss	14156037
CY2012	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13226732
CY2012	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P8Y
CY2012	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	5923675
CY2012	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	35000
CY2012	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-8332
CY2011Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30782000	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	368690	shares
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2884631
CY2012	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	602523
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue	931000
CY2012	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of Estimates</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> </div>
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7792
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1017000
CY2012	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2083964
CY2012	us-gaap	Interest Expense InterestExpense	56714
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.62
CY2012	rgen	Provision For Deferred Income Tax Expense Benefit ProvisionForDeferredIncomeTaxExpenseBenefit	-3197261
CY2012	rgen	Change In Fair Value Of Acquisition Related Contingent Consideration ChangeInFairValueOfAcquisitionRelatedContingentConsideration	610877
CY2012	rgen	Income Tax Reconciliation Gain On Bargain Purchase IncomeTaxReconciliationGainOnBargainPurchase	82422
CY2012	rgen	Deferred Tax Assets Valuation Allowance Increase Decrease DeferredTaxAssetsValuationAllowanceIncreaseDecrease	-10169000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	76000
CY2011Q1	us-gaap	Costs And Expenses CostsAndExpenses	7992000
CY2011Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2086000
CY2011Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3150000
CY2011Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2011Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	69000
CY2011Q1	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	376000
CY2012	rgen	Lease Agreement Area LeaseAgreementArea	45000	sqft
CY2012	rgen	Number Of Buildings Leased NumberOfBuildingsLeased	4	Building
CY2012	rgen	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	242629
CY2012	rgen	Government Grant GovernmentGrant	803000
CY2012	rgen	Number Of Years For Cumulative Pretax Loss Position NumberOfYearsForCumulativePretaxLossPosition	P3Y
CY2008	rgen	Lease Agreement Area LeaseAgreementArea	7350	sqft
CY2012	rgen	Effective Income Tax Rate Reconciliation Transaction Costs EffectiveIncomeTaxRateReconciliationTransactionCosts	0.000	pure
CY2012	rgen	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.021	pure
CY2012	rgen	Effective Income Tax Rate Reconciliation Bargain Purchase Gain EffectiveIncomeTaxRateReconciliationBargainPurchaseGain	-0.007	pure
CY2011Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2030000
CY2011Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2011Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3785000
CY2011Q1	us-gaap	Royalty Revenue RoyaltyRevenue	2756000
CY2011Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30782000	shares
CY2011Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1393000
CY2012Q2	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	537000
CY2012Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31149000	shares
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1778000
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2906000
CY2012Q2	us-gaap	Royalty Revenue RoyaltyRevenue	3865000
CY2012Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30845000	shares
CY2012Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	7345000
CY2012Q2	us-gaap	Revenues Revenues	15524000
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	1570000
CY2012Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3418000
CY2011Q1	us-gaap	Revenues Revenues	5906000
CY2011Q1	us-gaap	Net Income Loss NetIncomeLoss	-2030000
CY2011Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2438000
CY2011Q1	us-gaap	Interest Expense InterestExpense	13000
CY2011Q2	us-gaap	Costs And Expenses CostsAndExpenses	7775000
CY2011Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-121000
CY2011Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4359000
CY2011Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2011Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	66000
CY2011Q2	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	416000
CY2011Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30812000	shares
CY2011Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-55000
CY2011Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2011Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3517000
CY2011Q2	us-gaap	Royalty Revenue RoyaltyRevenue	3295000
CY2011Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30812000	shares
CY2011Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1553000
CY2011Q2	us-gaap	Revenues Revenues	7654000
CY2011Q2	us-gaap	Net Income Loss NetIncomeLoss	-55000
CY2011Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2289000
CY2012Q2	us-gaap	Costs And Expenses CostsAndExpenses	14206000
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	1318000
CY2012Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	11659000
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	458000
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2012Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	29000
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	208000
CY2012Q2	us-gaap	Interest Expense InterestExpense	27000
CY2012Q1	us-gaap	Costs And Expenses CostsAndExpenses	11657000
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	1167000
CY2012Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	9342000
CY2012Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	109000
CY2012Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2012Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	31000
CY2012Q1	us-gaap	Gain On Purchase Of Business GainOnPurchaseOfBusiness	314000
CY2011Q4	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	43000
CY2011Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2870000
CY2012Q1	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	462000
CY2012Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31010000	shares
CY2012Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1285000
CY2012Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2808000
CY2012Q1	us-gaap	Royalty Revenue RoyaltyRevenue	3482000
CY2012Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30730000	shares
CY2012Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5273000
CY2012Q1	us-gaap	Revenues Revenues	12824000
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	1226000
CY2012Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3428000
CY2012Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	59000
CY2012Q1	us-gaap	Interest Expense InterestExpense	22000
CY2011Q3	us-gaap	Costs And Expenses CostsAndExpenses	8079000
CY2011Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	552000
CY2011Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	5742000
CY2011Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2011Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	53000
CY2011Q3	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	418000
CY2011Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30934000	shares
CY2011Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	605000
CY2011Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2011Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3075000
CY2011Q3	us-gaap	Royalty Revenue RoyaltyRevenue	2889000
CY2011Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30797000	shares
CY2011Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2093000
CY2011Q3	us-gaap	Revenues Revenues	8631000
CY2011Q3	us-gaap	Net Income Loss NetIncomeLoss	605000
CY2011Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2493000
CY2011Q4	us-gaap	Costs And Expenses CostsAndExpenses	8703000
CY2011Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1538000
CY2011Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3114000
CY2011Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-623000
CY2011Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2011Q4	us-gaap	Gain On Purchase Of Business GainOnPurchaseOfBusiness	427000
CY2011Q4	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	481000
CY2011Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30715000	shares
CY2011Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2146000
CY2011Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2011Q4	us-gaap	Royalty Revenue RoyaltyRevenue	4051000
CY2011Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30715000	shares
CY2011Q4	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1511000
CY2011Q4	us-gaap	Revenues Revenues	7165000
CY2011Q4	us-gaap	Net Income Loss NetIncomeLoss	-2162000
CY2011Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4268000
CY2011Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	16000
CY2012Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-41000
CY2012Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.30
CY2012Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2343000
CY2012Q4	us-gaap	Royalty Revenue RoyaltyRevenue	9104000
CY2012Q4	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	62000
CY2012Q4	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	620000
CY2012Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31600000	shares
CY2012Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	6418000
CY2012Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
CY2012Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31132000	shares
CY2012Q4	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5920000
CY2012Q4	us-gaap	Revenues Revenues	18814000
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	9553000
CY2012Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3253000
CY2011Q4	us-gaap	Interest Expense InterestExpense	28000
CY2011Q4	rgen	Change In Fair Value Of Acquisition Related Contingent Consideration ChangeInFairValueOfAcquisitionRelatedContingentConsideration	-427000
CY2012Q3	us-gaap	Costs And Expenses CostsAndExpenses	12916000
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	2188000
CY2012Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	11123000
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-500000
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.06
CY2012Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	95000
CY2012Q3	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	594000
CY2012Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31256000	shares
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1790000
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.06
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2433000
CY2012Q3	us-gaap	Royalty Revenue RoyaltyRevenue	3981000
CY2012Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30948000	shares
CY2012Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6419000
CY2012Q3	us-gaap	Revenues Revenues	15104000
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	1806000
CY2012Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3126000
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-16000
CY2012Q3	us-gaap	Interest Expense InterestExpense	-7000
CY2012Q3	rgen	Change In Fair Value Of Acquisition Related Contingent Consideration ChangeInFairValueOfAcquisitionRelatedContingentConsideration	344000
CY2012Q4	us-gaap	Costs And Expenses CostsAndExpenses	12403000
CY2012Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	6411000
CY2012Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	9710000
CY2012Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3135000
CY2012Q4	us-gaap	Interest Expense InterestExpense	14000
CY2012Q4	rgen	Change In Fair Value Of Acquisition Related Contingent Consideration ChangeInFairValueOfAcquisitionRelatedContingentConsideration	267000

Files In Submission

Name	View Source	Status
0001193125-13-109050-index-headers.html	Edgar Link	pending
0001193125-13-109050-index.html	Edgar Link	pending
0001193125-13-109050.txt	Edgar Link	pending
R49.htm	Edgar Link	pending
0001193125-13-109050-xbrl.zip	Edgar Link	pending
d453782d10k.htm	Edgar Link	pending
d453782dex1025.htm	Edgar Link	pending
d453782dex211.htm	Edgar Link	pending
d453782dex231.htm	Edgar Link	pending
d453782dex311.htm	Edgar Link	pending
d453782dex312.htm	Edgar Link	pending
d453782dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g453782g68l40.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgen-20121231.xml	Edgar Link	completed
rgen-20121231.xsd	Edgar Link	pending
rgen-20121231_cal.xml	Edgar Link	unprocessable
rgen-20121231_def.xml	Edgar Link	unprocessable
rgen-20121231_lab.xml	Edgar Link	unprocessable
rgen-20121231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGEN
REPLIGEN CORP Stock $rgen

2012 Q4 Form 10-K Financial Statement

#000119312513109050 Filed on March 15, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGEN REPLIGEN CORP Stock $rgen

2012 Q4 Form 10-K Financial Statement

#000119312513109050 Filed on March 15, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGEN
REPLIGEN CORP Stock $rgen